Lund, Sweden, January 20, 2023 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its Year-end Report 2022 at 8:00 CET on February 2, 2023. All interested parties are invited to participate in a telephone conference, which will include a presentation of the year-end results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call. Link to presentation

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 020 3936 2999

United States: +1 646 664 1960

Participant access code: 031372

The webcast will be available on https://events.q4inc.com/attendee/195504216

Financial calendar and events 2023

Feb 2, 2023         Interim Report for January-December 2022

Feb 9, 2023         Mid-cap event, Frankfurt

Feb 23, 2023       Erik Penser Healthcare Seminar, Stockholm

Mar 7, 2023         Redeye Healthcare Seminar: Commercialization, Stockholm

Mar 16, 2023       Carnegie Nordic Healthcare Seminar 2023, Stockholm

Mar 30, 2023       2022 Annual Report

April 4, 2023        Guggenheim Healthcare Talks Rare Disease Days

April 20, 2023      Interim Report for January-March 2023

April 20 2023       Redeye investor forum, Gothenburg

April 21 2023       Redeye lunch presentation, Stockholm

April 25 2023       Kempen Life Sciences Conference 2023, Amsterdam

May 11, 2023       Erik Penser Company Day, Malmö

May 11, 2023       Redeye investor forum, Malmö

May 25, 2023       Erik Penser Company Day, Stockholm

June 14, 2023      Annual General Meeting 2023

July 20, 2023       Half-year Report for January-June 2023

Oct 19, 2023        Interim Report for January-September 2023